What You Should Know:
– WearLinq, a leader in wearable health monitoring, announced a strategic acquisition of AMI Cardiac Monitoring, LLC, a seasoned player in ambulatory cardiac monitoring.
– The acquisition, coupled with a recent $6.7M funding round, positions WearLinq to significantly expand access to their innovative eWave 6-lead ECG monitor and revolutionize the fight against atrial fibrillation (AFib), which recently received FDA 510(k) clearance.
Tackling the Silent Threat of AFib
AFib, a heart rhythm irregularity, affects one in three people in their lifetime. It increases stroke risk fivefold and often leads to heart failure. Yet, current diagnostic methods miss a significant portion of cases, with over 30% of patients receiving false negatives and needing retesting within six months.
WearLinq’s eWave: A Powerful Tool for Early Detection
WearLinq’s eWave 6-lead ECG device seeks to address these shortcomings. This wearable technology offers cardiologists a detailed, multidimensional view of the heart, ensuring accurate P-wave detection and exceptional ECG clarity. Here’s what sets the eWave apart:
- Patient Comfort: Designed for comfort and minimal intrusion, the eWave allows patients to maintain their daily routines while undergoing cardiac monitoring.
- Long-Term Monitoring: The device works seamlessly with a smartphone for extended monitoring periods. A convenient, AirPods-like charging case ensures continuous operation.
- Advanced Data Analysis: Integrated with a state-of-the-art cloud platform, the eWave provides near real-time data analysis and actionable insights for healthcare providers.
- Skin-like Adhesive Patches: WearLinq’s patent-pending adhesive patches ensure secure and comfortable wear.
Joe Knight Appointed to Board of Directors
The acquisition of AMI Cardiac Monitoring expands WearLinq’s ability to offer their eWave technology across all 50 states and provide expansive clinical services. Additionally, WearLinq welcomes industry veteran Joe Knight, co-inventor of iRhythm’s ZioPatch, to their Board of Directors. Knight’s expertise will be invaluable as WearLinq continues to innovate and disrupt the cardiac monitoring landscape.
"We are excited to join forces with WearLinq, a company at the forefront of cardiac monitoring innovation. This partnership aligns perfectly with our mission to provide exceptional diagnostic services," said Dorothy Glodek, Founder of AMI Cardiac Monitoring, LLC. "By integrating WearLinq's advanced 6-lead ECG technology with our extensive clinical expertise, we can offer unparalleled cardiac care to patients nationwide. Together, we are set to revolutionize the field of ambulatory cardiac monitoring, ensuring more accurate diagnoses and improved patient outcomes."
